Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain Ruffion

Showing results (191-200 of 218) with videos related to

Pageof 22
Sort By:
BJU International|April 21, 2025
External validation of current quality care metrics after radical nephroureterectomyIgor Duquesne, Pierre-Etienne Gabriel, Mohamad Abou Chakra, et al.
World Journal of Urology|February 22, 2019
Outcomes after salvage radical prostatectomy and first-line radiation therapy or HIFU for recurrent localized prostate cancer: results from a multicenter studyRomain Clery, Pietro Grande, Thomas Seisen, et al.
BJU International|August 14, 2013
Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumoursClémence Hollande, Pierre Colin, Thibault de La Motte Rouge, et al.
World Journal of Urology|August 18, 2022
Grade group 1 prostate cancer on biopsy: are we still missing aggressive disease in the era of image-directed therapy?Michael Baboudjian, Mathieu Roumiguié, Alexandre Peltier, et al.
The Lancet. Oncology|May 11, 2016
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trialChristian Carrie, Ali Hasbini, Guy de Laroche, et al.
World Journal of Urology|November 7, 2022
Heterogeneity of contemporary grade group 4 prostate cancer in radical prostatectomy specimensAlberto Martini, Alae Touzani, Jean-Baptiste Beauval, et al.
World Journal of Urology|December 12, 2012
The impact of lymph node status and features on oncological outcomes in urothelial carcinoma of the upper urinary tract (UTUC) treated by nephroureterectomyAdil Ouzzane, Pierre Colin, Tarek P Ghoneim, et al.
European Urology Oncology|January 4, 2026
Results of the Randomized Phase 3 AFU-GETUG-20 Trial Evaluating Adjuvant Leuprorelin Acetate After Radical Prostatectomy in Men with High-risk Localized Prostate CancerFrançois Rozet, Alain Ruffion, Pablo Lemercier, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 2, 2023
Intravesical injections of botulinum neurotoxin A to treat overactive bladder and/or detrusor overactivity related to multiple sclerosis: 5-Year continuation rate and specific risk factors for discontinuation-A study from the neuro-urology committee of the French Association of UrologyStéphanie Delaval, Pierre-Luc Dequirez, Claire Hentzen, et al.
The Lancet. Oncology|October 21, 2019
Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trialChristian Carrie, Nicolas Magné, Patricia Burban-Provost, et al.
Pageof 22

Showing results (191-200 of 218) with videos related to

Sort By:
Pageof 22
BJU International|April 21, 2025
External validation of current quality care metrics after radical nephroureterectomyIgor Duquesne, Pierre-Etienne Gabriel, Mohamad Abou Chakra, et al.
World Journal of Urology|February 22, 2019
Outcomes after salvage radical prostatectomy and first-line radiation therapy or HIFU for recurrent localized prostate cancer: results from a multicenter studyRomain Clery, Pietro Grande, Thomas Seisen, et al.
BJU International|August 14, 2013
Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumoursClémence Hollande, Pierre Colin, Thibault de La Motte Rouge, et al.
World Journal of Urology|August 18, 2022
Grade group 1 prostate cancer on biopsy: are we still missing aggressive disease in the era of image-directed therapy?Michael Baboudjian, Mathieu Roumiguié, Alexandre Peltier, et al.
The Lancet. Oncology|May 11, 2016
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trialChristian Carrie, Ali Hasbini, Guy de Laroche, et al.
World Journal of Urology|November 7, 2022
Heterogeneity of contemporary grade group 4 prostate cancer in radical prostatectomy specimensAlberto Martini, Alae Touzani, Jean-Baptiste Beauval, et al.
World Journal of Urology|December 12, 2012
The impact of lymph node status and features on oncological outcomes in urothelial carcinoma of the upper urinary tract (UTUC) treated by nephroureterectomyAdil Ouzzane, Pierre Colin, Tarek P Ghoneim, et al.
European Urology Oncology|January 4, 2026
Results of the Randomized Phase 3 AFU-GETUG-20 Trial Evaluating Adjuvant Leuprorelin Acetate After Radical Prostatectomy in Men with High-risk Localized Prostate CancerFrançois Rozet, Alain Ruffion, Pablo Lemercier, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 2, 2023
Intravesical injections of botulinum neurotoxin A to treat overactive bladder and/or detrusor overactivity related to multiple sclerosis: 5-Year continuation rate and specific risk factors for discontinuation-A study from the neuro-urology committee of the French Association of UrologyStéphanie Delaval, Pierre-Luc Dequirez, Claire Hentzen, et al.
The Lancet. Oncology|October 21, 2019
Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trialChristian Carrie, Nicolas Magné, Patricia Burban-Provost, et al.
Pageof 22